14-3-3η Protein, Disease Activity and Bone Mineral Density, in Female Patients With Rheumatoid Arthritis

Al-Azhar University45 enrolled

Overview

Is to investigate the relation between 14-3-3η protein, disease activity, and bone mineral density in female patients with rheumatoid arthritis.

Methods: all patients in the study will subject to: * Clinical assessment, WT, Height ,BMI, parity, medications, * DAS 28. * Serum 14-3-3η protein. * DEXA scan. Grouping: * Group I: RA Patients with low BMD. * Group II: RA Patients with normal BMD. * Group III: normal control.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rheumatoid Arthritis Osteoporosis

Interventions

14-3-3η Protein assayDIAGNOSTIC_TEST

blood sampling for assessment of serum 14-3-3η Protein

Eligibility

Sex: FEMALEMin age: 16 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Rheumatoid arthritis according to ACR 2010 criteria with at least one year duration. * Premenopausal females. * On conventional DMARD with maximum 5 mg steroids. Exclusion Criteria: * Biological treatment. * Previous antiresorptive treatment, or bone anabolics. * High dose corticosteroid. * Chronic renal or kidney disease. * Medications affecting bone metabolism. * Thyroid or adrenal dysfunction,

Locations (1)

Al-Azhar Faculty of medicine, Rheumatology Department

Cairo, Egypt

Outcomes

Primary Outcomes

14-3-3η Protein and RA disease activity

percent of active RA disease and study the correlation between 14-3-3η Protein and RA disease activity

Time frame: three months

Secondary Outcomes

14-3-3η Protein and osteoporosis in RA patients

percent of low BMD and study the correlation between 14-3-3η Protein and osteoporosis in RA patients

Time frame: three months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.